Skip directly to content

Afrique Moyen-Orient Étude épidémiologique cardiovasculaire (étude ACE) - Dyslipidémie

Protect your Patient’s Health

Dyslipidaemia is a common CV risk factor

Lipid abnormalities are associated with an increased risk of CV events. The ACE2 study reported that dyslipidaemia was the most prevalent CV risk factor observed in 70% of the study population. The prevalence of dyslipidaemia was reported to be more than 50% in all evaluated countries, with Kuwait having the highest prevalence (85%).1


Uncontrolled dyslipidaemia
The key element of dyslipidaemia was low HDL-C, which was observed in nearly 30% of patients. The majority (79%) of high-risk patients and many (34%) moderate-risk patients were not at their target LDL-C goals, suggesting uncontrolled disease.1
**NCEP, National Cholesterol Education Program.
Younger patients are found to be at risk
Although prevalence of dyslipidaemia was higher in older outpatients, it was particularly high in patients below the age of 40 years: one in two patients younger than 40 years had dyslipidaemia or were abdominally obese. Moreover, one new diagnosis of dyslipidaemia was recorded for every two outpatients without a prior diagnosis.1


Early identification is crucial to reducing disease burden
Early identification of CV risk factors such as dyslipidaemia, especially in the primary care settings, is crucial for reducing the onset and burden of CV disease. This study emphasizes the need for regular screening for risk factors, especially in younger individuals within the region who appear to be predisposed to CV disease.1
  1. Alsheikh Ali AA, Omar MI, Raal FJ, et al. Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study. PLoS One. 2014;9(8):e102830.
  2. The Africa Middle East Cardiovascular Epidemiological (ACE) study was funded by Pfizer


Pfizer Identification Number: WGFLIP1215092